SlideShare une entreprise Scribd logo
1  sur  41
Télécharger pour lire hors ligne
Dr. Jigar Vyas
Professor
Sigma Institute of Pharmacy
2
YSPM, YTC
 Ensuring uniformity in standards of
quality, efficacy of pharmaceutical
products.
 BA/BE focus on the release of the
drug from the dosage form and
absorption in to the systemic
circulation.
 BE for the comparison of the two drug,
several test method are given to
determine the equivalence.
Important Pharmacokinetic
Parameters
 AUC: area under the concentration-time
curve measure of the extent of
bioavailability
 Cmax: the observed maximum
concentration of drug measure of both
the rate of absorption and the extent of
bioavailability
 tmax: the time after administration of drug
at which Cmax is observed measure of
the rate of absorption
Plasma concentration time
profile
Cmax
Tmax
AUC
time
concentration
Pharmacokinetics
conc. vs time
 BIOAVAILABILITY: It is relative
amount of drug from an administered
dosage form which enters the
systemic circulation and rate at which
the drug appears in the systemic
circulation.
 The extent and rate at which its active
moiety is delivered from pharmaceutical
form and becomes available in the
systemic circulation
Scheme of Oral Dosage Form
Oral Bioavailability (%F)
Human Intestinal
Absorption (HIA)
1,2 – Stability + Solubility
3 – Passive + Active Tr.
4 – Pgp efflux + CYP 3A4
Why do we care about
BIOAVAILABILITY
?
 The “true dose” is not the drug
swallowed;
BUT is the drug available to exert its
effect.
• Dissolution
• Absorption
• Survive metabolism
Why do we care about
BIOAVAILABILITY?
 May have a drug with very low
bioavailability.
• Dosage form or drug may not dissolve
readily.
• Drug may not be readily pass across
biological membranes (i.e. be absorbed).
• Drug may be extensively metabolized
during absorption process (first-pass, gut
wall, liver).
 Important component of overall variability
i.e. Variable bioavailability may produce
variable exposure.
Pharmaceutical Equivalents
 contain the same amount of the same
active substance in the same dosage
form
 meet the same or comparable
standards
 intended to be administered by the
same route
Pharmaceutical equivalence by itself
does not
necessarily imply therapeutic
Pharmaceutical Equivalents
Test Reference
Possible Differences
Drug particle size
Excipients
Manufacturing Equipment or Process
Site of manufacture
Could lead to differences in product performance
in vivo
Possible Bioinequivalence
Bioequivalence
Two products are bioequivalent if
they are pharmaceutically equivalent
bioavailabilities (both rate and extent)
after administration in the same molar
dose are similar to such a degree that
their effects can be expected to be
essentially the same
Therapeutic equivalence
Two products are therapeutically equivalent if
pharmaceutically equivalent
their effects, with respect to both efficacy and
safety, will be essentially the same as derived from
appropriate studies
◦ bioequivalence studies
◦ pharmacodynamic studies
◦ clinical studies
◦ in vitro studies
Bioequivalence (BE):
the absence of a significant difference in
the rate
and extent to which the active ingredient
or active
moiety in pharmaceutical equivalents or
pharmaceutical alternatives becomes
available at
the site of drug action when administered
at the
same molar dose under similar conditions
in
an appropriately designed study
Need of bioequivalence
studies
 No clinical studies have been
performed in patients with the Generic
Product to support its Efficacy and
Safety.
 With data to support similar in vivo
performance (= Bioequivalence)
Efficacy and Safety
data can be extrapolated from the
Innovator Product to the Generic
Product.
Bioequivalence (BE):
Ultimate: Bioequivalence studies impact
of changes to the dosage form process
after pivotal studies commence to
ensure product on the market is
comparable to that upon which the
efficacy is based
Establish that a new formulation has therapeutic
equivalence in the rate and extent of absorption to
the reference drug product.
Important for linking the commercial drug product
to clinical trial material at time of NDA.
Important for post-approval changes in the
marketed drug formulation.
Bioequivalence
90
80
70
60
50
40
30
20
10
0
0 5 10 20 25 30
15
Time
(hours)
Concentration
(ng/mL)
Test/Generic
Reference/Brand
Goals of BE
Ultimate: Bioequivalence studies impact
of changes to the dosage form process
after pivotal studies commence to
ensure product on the market is
comparable to
that upon which the efficacy is based
Establish that a new formulation has therapeutic
equivalence in the rate and extent of absorption to
the reference drug product.
Important for linking the commercial drug product
to clinical trial material at time of NDA
Important for post-approval changes in the
marketed drug formulation
NDA vs. ANDA Review
Process
Innovator and generic drug
Original Drug
NDARequirements
1. Chemistry
2. Manufacturing
3. Controls
4. Labeling
5. Testing
6. Animal Studies
7. Clinical Studies
(Bioavailability/Bioequivalence)
Generic Drug
ANDARequirements
1. Chemistry
2. Manufacturing
3. Controls
4. Labeling
5. Testing
6. Bioequivalence Study (In
Vivo, In vitro)
NDA vs. ANDA Review
Process
 Note: Generic drug applications are
termed "abbreviated" because they are
generally
not required to include preclinical
(animal) and clinical (human) data to
establish safety and effectiveness.
 Instead, generic applicants must
scientifically demonstrate that their
product is bioequivalent
(i.e., performs in the same manner as the
original; drug).
21
Current BE* Requirements
Major Regulatory Agencies
U.S. Food and Drug Administration
(FDA)
Health Canada
Committee for Proprietary Medicinal
Products (CPMP), Europe
National Institute of Health Sciences
(NIHS), Japan
*BE = Bioequivalence
22
Current BE Requirements
FDA*
AUC: 90% Confidence Interval Limits
80-125%
Cmax: 90% Confidence Interval Limits
80-125%
Criteria applied to drugs of low and
high variability
23
Current BE Requirements
Health Canada
AUC: 90% Confidence Interval Limits
80-125%
Cmax: Mean T/R ratio (point estimate)
between 80-125% (T=test,
R=reference)
Criteria judged flexible enough to deal
with highly variable drugs*
24
Current BE Requirements
CPMP*
AUC: 90% Confidence Interval Limits
80-125%
Cmax: 90% Confidence Interval Limits
80-125%
Cmax: “In certain cases a wider interval
is acceptable (e.g., 75-133%)
25
Current BE Requirements
NIHS (Japan)*
AUC: 90% Confidence Interval Limits
80-125%
Cmax: 90% Confidence Interval Limits
80-125%
In cases of failure, add-on studies are
acceptable (provided other criteria are
met)
Study Design: Basic design
consideration
 Minimize variability to formulations
 Minimize bias
To compare performance of two
products!!!
Study Designs
 Single-dose, two-way crossover,
fasted
 Single-dose, two-way crossover, fed
Alternative
 Single-dose, parallel, fasted (Long
half-life)
 Single-dose, replicate design (Highly
Variable Drugs)
 Multiple-dose, two-way crossover,
fasted (Less Sensitive, non-linear
Study Designs
 Duration of washout period for cross-
over design
- should be approximately > 5 times the
plasma apparent terminal half-life
- However, should be adjusted
accordingly for drugs with complex
kinetic model
Study Designs
 Sample size determination(dose)
- significant level (α = 0.05)
- 20% deviation from the reference
product
- power > 80%
 Sample time determination
- adequate data points around tmax
- 3 or more time of t1/2 to around AUC0-t
= at least 80% AUC0-inf
Study Designs
 Subjects? (Inclusion/exclusion criteria)
LABEL
 Healthy subjects (male and female)
 18-55 years old,
 Non-smokers/without a history of alcohol or drug
abuse Medical history/Clinical Lab test values
must be within normal ranges
 Contraindication
 Refrain from the concomitants use of any
medications or food interact with GI, renal, liver
function from 28 days prior study Day1
through the safety.
Study Design:
 Crossover Design
 x Crossover design
 A single-dose bioequivalence study is
performed in normal, healthy, adult
volunteers.
 18 subjects are hired (Male or Female?)
 The subjects are randomly selected for
each group and the sequence of drug
administration is randomly assigned.
 One-week washout periods
 Fasted or Fed?
Statistical Analysis
(Two one-sided
Tests Procedure)
 AUC (Extent) and Cmax (Rate) – Log
transformation
i.e. 90% Confidence Intervals (CI) of the
difference in Log (AUCt) –Log (AUCR)
must fit between 80%-125%
Bioanalytical Method
Validation
Method Validation should include
Accuracy
Precision Sensitivity
Specificity Recovery Stability
Bioanalytical Method
Validation
 Accuracy
Closeness of determined value to the
true
Value
The acceptance criteria is mean value <
15% deviation from the true value.
At LOQ(limit of quantification), 20%
deviation is acceptable
Bioanalytical Method
Validation
 Precision
The closeness of replicate
determinations of
a sample by an assay
The acceptance criteria is < 15%
CV,(closeness value) at
20% LOQ(limit of quantification)
Bioanalytical Method
Validation
 Sensitivity
The limit of quantitation is the lowest
concentration which can be measured
with acceptable accuracy and precision
 Selectivity
Ability of the method to measure only what
it
is intended to measure in the presence of
other components in the sample. Blank
samples of the biological matrix should be
tested for the interfering peak.
Bioanalytical Method
Validation
 Recovery
The extraction efficiency of an analytical
process, reported as an percentage of
the
known amount of an analyte. Recovery
does not have to be 100% but the
extent of recovery of internal standard
and analyte should be consistent.
Bioanalytical Method
Validation
 Stability
During, sample collection , sample
storage
and sample analysis process, the
stability of
drug in matrix should be conducted
Conclusion
 Establish that a new formulation has
therapeutic equivalence in the rate
and extent of absorption to the
reference drug product.
 Important for linking the commercial
drug product to clinical trial material at
time of NDA.
 Important for post-approval changes
in the marketed drug formulation.
References
 D.M.Brahmankar, S.B.Jaiswal
Biopharmaceutics and
Pharmacokinetics A Treatise Vallabh
Prakashan pg.no.315-363.
BA-BE Bio-availability and Bio-equivalency

Contenu connexe

Tendances

Quality by design (qb d).
Quality by design (qb d).Quality by design (qb d).
Quality by design (qb d).sawantanil
 
Bioavailability and bioequivalence
Bioavailability and bioequivalenceBioavailability and bioequivalence
Bioavailability and bioequivalencemuliksudip
 
Bioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence StudiesBioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence StudiesPranav Sopory
 
Bioanalytical Method Validation
Bioanalytical Method ValidationBioanalytical Method Validation
Bioanalytical Method ValidationShivani Chaudhari
 
Bioanalytical Method Validation Fda Perspective
Bioanalytical Method Validation   Fda PerspectiveBioanalytical Method Validation   Fda Perspective
Bioanalytical Method Validation Fda PerspectiveDebanjan (Deb) Das
 
Bioequivalence studies : A statistical approach through "R"
Bioequivalence  studies : A statistical approach through "R"Bioequivalence  studies : A statistical approach through "R"
Bioequivalence studies : A statistical approach through "R"Lavkush Upadhyay
 
S2229 4708%2810%2911004-8
S2229 4708%2810%2911004-8S2229 4708%2810%2911004-8
S2229 4708%2810%2911004-8Nacho Bressán
 
Bioanlytical method development
Bioanlytical method developmentBioanlytical method development
Bioanlytical method developmentSagar Savale
 
The EMA Bioanalytical Method Validation Guideline: process, history, discussi...
The EMA Bioanalytical Method Validation Guideline: process, history, discussi...The EMA Bioanalytical Method Validation Guideline: process, history, discussi...
The EMA Bioanalytical Method Validation Guideline: process, history, discussi...Peter van Amsterdam
 
Global Regulatory Issues: one BA method, one validation, one report ...
Global Regulatory Issues: one BA method, one validation, one report ...Global Regulatory Issues: one BA method, one validation, one report ...
Global Regulatory Issues: one BA method, one validation, one report ...Peter van Amsterdam
 
Four Levels of In-Vitro-In-Vivo Correlation
Four Levels of In-Vitro-In-Vivo CorrelationFour Levels of In-Vitro-In-Vivo Correlation
Four Levels of In-Vitro-In-Vivo CorrelationBhaswat Chakraborty
 
Parameters to evaluate Bioequivalence
Parameters to evaluate BioequivalenceParameters to evaluate Bioequivalence
Parameters to evaluate BioequivalenceVinitha Nair
 
Invitro drug product performance
Invitro drug product performance Invitro drug product performance
Invitro drug product performance silambarasan I
 
Track 9-1 Designing of bioequivalence studies of anticancer products Protocol...
Track 9-1 Designing of bioequivalence studies of anticancer products Protocol...Track 9-1 Designing of bioequivalence studies of anticancer products Protocol...
Track 9-1 Designing of bioequivalence studies of anticancer products Protocol...Vikas Kumar, M. Pharm., M.B.A, PMP
 

Tendances (20)

Quality by design (qb d).
Quality by design (qb d).Quality by design (qb d).
Quality by design (qb d).
 
Bioavailability and bioequivalence
Bioavailability and bioequivalenceBioavailability and bioequivalence
Bioavailability and bioequivalence
 
Bioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence StudiesBioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence Studies
 
Bioanalytical Method Validation
Bioanalytical Method ValidationBioanalytical Method Validation
Bioanalytical Method Validation
 
Bioanalytical method validation emea
Bioanalytical method validation emeaBioanalytical method validation emea
Bioanalytical method validation emea
 
Bioanalytical Method Validation Fda Perspective
Bioanalytical Method Validation   Fda PerspectiveBioanalytical Method Validation   Fda Perspective
Bioanalytical Method Validation Fda Perspective
 
Bioequivalence studies : A statistical approach through "R"
Bioequivalence  studies : A statistical approach through "R"Bioequivalence  studies : A statistical approach through "R"
Bioequivalence studies : A statistical approach through "R"
 
Bio-equivalence of Generic Drug
Bio-equivalence of Generic DrugBio-equivalence of Generic Drug
Bio-equivalence of Generic Drug
 
Dissolution & Alternate Analytical Method
Dissolution & Alternate Analytical MethodDissolution & Alternate Analytical Method
Dissolution & Alternate Analytical Method
 
S2229 4708%2810%2911004-8
S2229 4708%2810%2911004-8S2229 4708%2810%2911004-8
S2229 4708%2810%2911004-8
 
Bioanlytical method development
Bioanlytical method developmentBioanlytical method development
Bioanlytical method development
 
Bioequivalence
BioequivalenceBioequivalence
Bioequivalence
 
The EMA Bioanalytical Method Validation Guideline: process, history, discussi...
The EMA Bioanalytical Method Validation Guideline: process, history, discussi...The EMA Bioanalytical Method Validation Guideline: process, history, discussi...
The EMA Bioanalytical Method Validation Guideline: process, history, discussi...
 
Global Regulatory Issues: one BA method, one validation, one report ...
Global Regulatory Issues: one BA method, one validation, one report ...Global Regulatory Issues: one BA method, one validation, one report ...
Global Regulatory Issues: one BA method, one validation, one report ...
 
Babe
BabeBabe
Babe
 
Four Levels of In-Vitro-In-Vivo Correlation
Four Levels of In-Vitro-In-Vivo CorrelationFour Levels of In-Vitro-In-Vivo Correlation
Four Levels of In-Vitro-In-Vivo Correlation
 
Parameters to evaluate Bioequivalence
Parameters to evaluate BioequivalenceParameters to evaluate Bioequivalence
Parameters to evaluate Bioequivalence
 
Invitro drug product performance
Invitro drug product performance Invitro drug product performance
Invitro drug product performance
 
Track 9-1 Designing of bioequivalence studies of anticancer products Protocol...
Track 9-1 Designing of bioequivalence studies of anticancer products Protocol...Track 9-1 Designing of bioequivalence studies of anticancer products Protocol...
Track 9-1 Designing of bioequivalence studies of anticancer products Protocol...
 
Bioequivalence
BioequivalenceBioequivalence
Bioequivalence
 

Similaire à BA-BE Bio-availability and Bio-equivalency

Bioavailability and bioequivalence of Drug Productppt2.pptx
Bioavailability and bioequivalence of Drug Productppt2.pptxBioavailability and bioequivalence of Drug Productppt2.pptx
Bioavailability and bioequivalence of Drug Productppt2.pptxabhisheksinghcompute
 
Bioavailability and bioequivalence of Drug Productppt2.pptx
Bioavailability and bioequivalence of Drug Productppt2.pptxBioavailability and bioequivalence of Drug Productppt2.pptx
Bioavailability and bioequivalence of Drug Productppt2.pptxabhisheksinghcompute
 
Bioavailability and bioequivalence of Drug Productppt2.pptx
Bioavailability and bioequivalence of Drug Productppt2.pptxBioavailability and bioequivalence of Drug Productppt2.pptx
Bioavailability and bioequivalence of Drug Productppt2.pptxabhisheksinghcompute
 
Bioequiuvalence and drug product assessment
Bioequiuvalence and drug product assessmentBioequiuvalence and drug product assessment
Bioequiuvalence and drug product assessmentNishaN19p7504
 
Bioavailability and bioequivalence studies
Bioavailability and bioequivalence studiesBioavailability and bioequivalence studies
Bioavailability and bioequivalence studiesNagaraju Ravouru
 
Anita bioavailability seminar
Anita bioavailability seminarAnita bioavailability seminar
Anita bioavailability seminaranita malusare
 
Bioequivalence biowaiver and ivivc studies 2014 new
Bioequivalence biowaiver and ivivc studies 2014 newBioequivalence biowaiver and ivivc studies 2014 new
Bioequivalence biowaiver and ivivc studies 2014 newAsra Hameed
 
Bioequivalance and drug product assesment seminar 2020
Bioequivalance and drug product assesment seminar 2020Bioequivalance and drug product assesment seminar 2020
Bioequivalance and drug product assesment seminar 2020SoumyadipGhosh19
 
Bioavailability and bioequivalance studies and Regulatory aspects
Bioavailability and bioequivalance studies and Regulatory aspectsBioavailability and bioequivalance studies and Regulatory aspects
Bioavailability and bioequivalance studies and Regulatory aspectsRumel Dey
 
Quality Assurance in Pharmaceuticals
Quality Assurance in PharmaceuticalsQuality Assurance in Pharmaceuticals
Quality Assurance in PharmaceuticalsPharmaguideline
 
Bioequivalence studies ( Evaluation and Study design)
Bioequivalence studies ( Evaluation and Study design)Bioequivalence studies ( Evaluation and Study design)
Bioequivalence studies ( Evaluation and Study design)Selim Akhtar
 
B.e and drug product assesment
B.e and drug product assesmentB.e and drug product assesment
B.e and drug product assesmentVaishnaviRaut6
 
Biopharmaceutics Applications in drug studies
Biopharmaceutics Applications in drug studiesBiopharmaceutics Applications in drug studies
Biopharmaceutics Applications in drug studiesRaviKumarReddyJuturi
 
10th VOF - 11.2 Bioequivalence..pptx
10th VOF - 11.2 Bioequivalence..pptx10th VOF - 11.2 Bioequivalence..pptx
10th VOF - 11.2 Bioequivalence..pptxsweed5
 
10th VOF - 11.2 Bioequivalence..pptx
10th VOF - 11.2 Bioequivalence..pptx10th VOF - 11.2 Bioequivalence..pptx
10th VOF - 11.2 Bioequivalence..pptxNirmalAli1
 
USFDA bio analytical method development and validation
USFDA bio analytical method development and validationUSFDA bio analytical method development and validation
USFDA bio analytical method development and validationKethana Nellore
 
Bioequivalence and drug product assessment
Bioequivalence and drug product assessmentBioequivalence and drug product assessment
Bioequivalence and drug product assessmentDipakKumarGupta3
 

Similaire à BA-BE Bio-availability and Bio-equivalency (20)

Bioavailability and bioequivalence of Drug Productppt2.pptx
Bioavailability and bioequivalence of Drug Productppt2.pptxBioavailability and bioequivalence of Drug Productppt2.pptx
Bioavailability and bioequivalence of Drug Productppt2.pptx
 
Bioavailability and bioequivalence of Drug Productppt2.pptx
Bioavailability and bioequivalence of Drug Productppt2.pptxBioavailability and bioequivalence of Drug Productppt2.pptx
Bioavailability and bioequivalence of Drug Productppt2.pptx
 
Bioavailability and bioequivalence of Drug Productppt2.pptx
Bioavailability and bioequivalence of Drug Productppt2.pptxBioavailability and bioequivalence of Drug Productppt2.pptx
Bioavailability and bioequivalence of Drug Productppt2.pptx
 
Babe bppk
Babe bppkBabe bppk
Babe bppk
 
Bioequiuvalence and drug product assessment
Bioequiuvalence and drug product assessmentBioequiuvalence and drug product assessment
Bioequiuvalence and drug product assessment
 
Bioavailability and bioequivalence studies
Bioavailability and bioequivalence studiesBioavailability and bioequivalence studies
Bioavailability and bioequivalence studies
 
Anita bioavailability seminar
Anita bioavailability seminarAnita bioavailability seminar
Anita bioavailability seminar
 
Bioequivalence biowaiver and ivivc studies 2014 new
Bioequivalence biowaiver and ivivc studies 2014 newBioequivalence biowaiver and ivivc studies 2014 new
Bioequivalence biowaiver and ivivc studies 2014 new
 
Bioequivalance and drug product assesment seminar 2020
Bioequivalance and drug product assesment seminar 2020Bioequivalance and drug product assesment seminar 2020
Bioequivalance and drug product assesment seminar 2020
 
Bioavailability and bioequivalance studies and Regulatory aspects
Bioavailability and bioequivalance studies and Regulatory aspectsBioavailability and bioequivalance studies and Regulatory aspects
Bioavailability and bioequivalance studies and Regulatory aspects
 
Quality Assurance in Pharmaceuticals
Quality Assurance in PharmaceuticalsQuality Assurance in Pharmaceuticals
Quality Assurance in Pharmaceuticals
 
Bioequivalence studies ( Evaluation and Study design)
Bioequivalence studies ( Evaluation and Study design)Bioequivalence studies ( Evaluation and Study design)
Bioequivalence studies ( Evaluation and Study design)
 
B.e and drug product assesment
B.e and drug product assesmentB.e and drug product assesment
B.e and drug product assesment
 
Biopharmaceutics Applications in drug studies
Biopharmaceutics Applications in drug studiesBiopharmaceutics Applications in drug studies
Biopharmaceutics Applications in drug studies
 
10th VOF - 11.2 Bioequivalence..pptx
10th VOF - 11.2 Bioequivalence..pptx10th VOF - 11.2 Bioequivalence..pptx
10th VOF - 11.2 Bioequivalence..pptx
 
10th VOF - 11.2 Bioequivalence..pptx
10th VOF - 11.2 Bioequivalence..pptx10th VOF - 11.2 Bioequivalence..pptx
10th VOF - 11.2 Bioequivalence..pptx
 
Bioequivalence studies
Bioequivalence studiesBioequivalence studies
Bioequivalence studies
 
USFDA bio analytical method development and validation
USFDA bio analytical method development and validationUSFDA bio analytical method development and validation
USFDA bio analytical method development and validation
 
Bioequivalence and drug product assessment
Bioequivalence and drug product assessmentBioequivalence and drug product assessment
Bioequivalence and drug product assessment
 
validation
validationvalidation
validation
 

Plus de Dr. Jigar Vyas

Scaleup techniques for production of tablets 212
Scaleup techniques for production of tablets 212Scaleup techniques for production of tablets 212
Scaleup techniques for production of tablets 212Dr. Jigar Vyas
 
Scale up techniques in the production of sterile products &amp; ophthalmic pr...
Scale up techniques in the production of sterile products &amp; ophthalmic pr...Scale up techniques in the production of sterile products &amp; ophthalmic pr...
Scale up techniques in the production of sterile products &amp; ophthalmic pr...Dr. Jigar Vyas
 
CTD (common technical document)
CTD (common technical document)CTD (common technical document)
CTD (common technical document)Dr. Jigar Vyas
 
Copp- Certificate of Pharmaceutical Products
Copp- Certificate of Pharmaceutical ProductsCopp- Certificate of Pharmaceutical Products
Copp- Certificate of Pharmaceutical ProductsDr. Jigar Vyas
 
Cdsco-Central Drugs Standard Control Organisation
Cdsco-Central Drugs Standard Control OrganisationCdsco-Central Drugs Standard Control Organisation
Cdsco-Central Drugs Standard Control OrganisationDr. Jigar Vyas
 
Semi solid dosage forms
Semi solid dosage forms Semi solid dosage forms
Semi solid dosage forms Dr. Jigar Vyas
 
Regulatory affair - Introduction
Regulatory affair - IntroductionRegulatory affair - Introduction
Regulatory affair - IntroductionDr. Jigar Vyas
 
NDA- New Drug Application
NDA- New Drug ApplicationNDA- New Drug Application
NDA- New Drug ApplicationDr. Jigar Vyas
 
INDA- Investigation New Drug Application
INDA- Investigation New Drug ApplicationINDA- Investigation New Drug Application
INDA- Investigation New Drug ApplicationDr. Jigar Vyas
 
Clean rooms in Injectables
Clean rooms in InjectablesClean rooms in Injectables
Clean rooms in InjectablesDr. Jigar Vyas
 

Plus de Dr. Jigar Vyas (15)

Supac
SupacSupac
Supac
 
Scaleup techniques for production of tablets 212
Scaleup techniques for production of tablets 212Scaleup techniques for production of tablets 212
Scaleup techniques for production of tablets 212
 
Scale up techniques in the production of sterile products &amp; ophthalmic pr...
Scale up techniques in the production of sterile products &amp; ophthalmic pr...Scale up techniques in the production of sterile products &amp; ophthalmic pr...
Scale up techniques in the production of sterile products &amp; ophthalmic pr...
 
Pilot plant
Pilot plantPilot plant
Pilot plant
 
CTD (common technical document)
CTD (common technical document)CTD (common technical document)
CTD (common technical document)
 
Copp- Certificate of Pharmaceutical Products
Copp- Certificate of Pharmaceutical ProductsCopp- Certificate of Pharmaceutical Products
Copp- Certificate of Pharmaceutical Products
 
Cdsco-Central Drugs Standard Control Organisation
Cdsco-Central Drugs Standard Control OrganisationCdsco-Central Drugs Standard Control Organisation
Cdsco-Central Drugs Standard Control Organisation
 
Semi solid dosage forms
Semi solid dosage forms Semi solid dosage forms
Semi solid dosage forms
 
Regulatory affair - Introduction
Regulatory affair - IntroductionRegulatory affair - Introduction
Regulatory affair - Introduction
 
Process validation
Process validationProcess validation
Process validation
 
NDA Vs ANDA
NDA Vs ANDANDA Vs ANDA
NDA Vs ANDA
 
NDA- New Drug Application
NDA- New Drug ApplicationNDA- New Drug Application
NDA- New Drug Application
 
INDA- Investigation New Drug Application
INDA- Investigation New Drug ApplicationINDA- Investigation New Drug Application
INDA- Investigation New Drug Application
 
DMF- Drug Master File
DMF- Drug Master FileDMF- Drug Master File
DMF- Drug Master File
 
Clean rooms in Injectables
Clean rooms in InjectablesClean rooms in Injectables
Clean rooms in Injectables
 

Dernier

SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 

Dernier (20)

SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 

BA-BE Bio-availability and Bio-equivalency

  • 1. Dr. Jigar Vyas Professor Sigma Institute of Pharmacy
  • 3.  Ensuring uniformity in standards of quality, efficacy of pharmaceutical products.  BA/BE focus on the release of the drug from the dosage form and absorption in to the systemic circulation.  BE for the comparison of the two drug, several test method are given to determine the equivalence.
  • 4. Important Pharmacokinetic Parameters  AUC: area under the concentration-time curve measure of the extent of bioavailability  Cmax: the observed maximum concentration of drug measure of both the rate of absorption and the extent of bioavailability  tmax: the time after administration of drug at which Cmax is observed measure of the rate of absorption
  • 6.  BIOAVAILABILITY: It is relative amount of drug from an administered dosage form which enters the systemic circulation and rate at which the drug appears in the systemic circulation.  The extent and rate at which its active moiety is delivered from pharmaceutical form and becomes available in the systemic circulation
  • 7. Scheme of Oral Dosage Form Oral Bioavailability (%F) Human Intestinal Absorption (HIA) 1,2 – Stability + Solubility 3 – Passive + Active Tr. 4 – Pgp efflux + CYP 3A4
  • 8. Why do we care about BIOAVAILABILITY ?  The “true dose” is not the drug swallowed; BUT is the drug available to exert its effect. • Dissolution • Absorption • Survive metabolism
  • 9. Why do we care about BIOAVAILABILITY?  May have a drug with very low bioavailability. • Dosage form or drug may not dissolve readily. • Drug may not be readily pass across biological membranes (i.e. be absorbed). • Drug may be extensively metabolized during absorption process (first-pass, gut wall, liver).  Important component of overall variability i.e. Variable bioavailability may produce variable exposure.
  • 10. Pharmaceutical Equivalents  contain the same amount of the same active substance in the same dosage form  meet the same or comparable standards  intended to be administered by the same route Pharmaceutical equivalence by itself does not necessarily imply therapeutic
  • 11. Pharmaceutical Equivalents Test Reference Possible Differences Drug particle size Excipients Manufacturing Equipment or Process Site of manufacture Could lead to differences in product performance in vivo Possible Bioinequivalence
  • 12. Bioequivalence Two products are bioequivalent if they are pharmaceutically equivalent bioavailabilities (both rate and extent) after administration in the same molar dose are similar to such a degree that their effects can be expected to be essentially the same
  • 13. Therapeutic equivalence Two products are therapeutically equivalent if pharmaceutically equivalent their effects, with respect to both efficacy and safety, will be essentially the same as derived from appropriate studies ◦ bioequivalence studies ◦ pharmacodynamic studies ◦ clinical studies ◦ in vitro studies
  • 14. Bioequivalence (BE): the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study
  • 15. Need of bioequivalence studies  No clinical studies have been performed in patients with the Generic Product to support its Efficacy and Safety.  With data to support similar in vivo performance (= Bioequivalence) Efficacy and Safety data can be extrapolated from the Innovator Product to the Generic Product.
  • 16. Bioequivalence (BE): Ultimate: Bioequivalence studies impact of changes to the dosage form process after pivotal studies commence to ensure product on the market is comparable to that upon which the efficacy is based Establish that a new formulation has therapeutic equivalence in the rate and extent of absorption to the reference drug product. Important for linking the commercial drug product to clinical trial material at time of NDA. Important for post-approval changes in the marketed drug formulation.
  • 17. Bioequivalence 90 80 70 60 50 40 30 20 10 0 0 5 10 20 25 30 15 Time (hours) Concentration (ng/mL) Test/Generic Reference/Brand
  • 18. Goals of BE Ultimate: Bioequivalence studies impact of changes to the dosage form process after pivotal studies commence to ensure product on the market is comparable to that upon which the efficacy is based Establish that a new formulation has therapeutic equivalence in the rate and extent of absorption to the reference drug product. Important for linking the commercial drug product to clinical trial material at time of NDA Important for post-approval changes in the marketed drug formulation
  • 19. NDA vs. ANDA Review Process Innovator and generic drug Original Drug NDARequirements 1. Chemistry 2. Manufacturing 3. Controls 4. Labeling 5. Testing 6. Animal Studies 7. Clinical Studies (Bioavailability/Bioequivalence) Generic Drug ANDARequirements 1. Chemistry 2. Manufacturing 3. Controls 4. Labeling 5. Testing 6. Bioequivalence Study (In Vivo, In vitro)
  • 20. NDA vs. ANDA Review Process  Note: Generic drug applications are termed "abbreviated" because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness.  Instead, generic applicants must scientifically demonstrate that their product is bioequivalent (i.e., performs in the same manner as the original; drug).
  • 21. 21 Current BE* Requirements Major Regulatory Agencies U.S. Food and Drug Administration (FDA) Health Canada Committee for Proprietary Medicinal Products (CPMP), Europe National Institute of Health Sciences (NIHS), Japan *BE = Bioequivalence
  • 22. 22 Current BE Requirements FDA* AUC: 90% Confidence Interval Limits 80-125% Cmax: 90% Confidence Interval Limits 80-125% Criteria applied to drugs of low and high variability
  • 23. 23 Current BE Requirements Health Canada AUC: 90% Confidence Interval Limits 80-125% Cmax: Mean T/R ratio (point estimate) between 80-125% (T=test, R=reference) Criteria judged flexible enough to deal with highly variable drugs*
  • 24. 24 Current BE Requirements CPMP* AUC: 90% Confidence Interval Limits 80-125% Cmax: 90% Confidence Interval Limits 80-125% Cmax: “In certain cases a wider interval is acceptable (e.g., 75-133%)
  • 25. 25 Current BE Requirements NIHS (Japan)* AUC: 90% Confidence Interval Limits 80-125% Cmax: 90% Confidence Interval Limits 80-125% In cases of failure, add-on studies are acceptable (provided other criteria are met)
  • 26. Study Design: Basic design consideration  Minimize variability to formulations  Minimize bias To compare performance of two products!!!
  • 27. Study Designs  Single-dose, two-way crossover, fasted  Single-dose, two-way crossover, fed Alternative  Single-dose, parallel, fasted (Long half-life)  Single-dose, replicate design (Highly Variable Drugs)  Multiple-dose, two-way crossover, fasted (Less Sensitive, non-linear
  • 28. Study Designs  Duration of washout period for cross- over design - should be approximately > 5 times the plasma apparent terminal half-life - However, should be adjusted accordingly for drugs with complex kinetic model
  • 29. Study Designs  Sample size determination(dose) - significant level (α = 0.05) - 20% deviation from the reference product - power > 80%  Sample time determination - adequate data points around tmax - 3 or more time of t1/2 to around AUC0-t = at least 80% AUC0-inf
  • 30. Study Designs  Subjects? (Inclusion/exclusion criteria) LABEL  Healthy subjects (male and female)  18-55 years old,  Non-smokers/without a history of alcohol or drug abuse Medical history/Clinical Lab test values must be within normal ranges  Contraindication  Refrain from the concomitants use of any medications or food interact with GI, renal, liver function from 28 days prior study Day1 through the safety.
  • 31. Study Design:  Crossover Design  x Crossover design  A single-dose bioequivalence study is performed in normal, healthy, adult volunteers.  18 subjects are hired (Male or Female?)  The subjects are randomly selected for each group and the sequence of drug administration is randomly assigned.  One-week washout periods  Fasted or Fed?
  • 32. Statistical Analysis (Two one-sided Tests Procedure)  AUC (Extent) and Cmax (Rate) – Log transformation i.e. 90% Confidence Intervals (CI) of the difference in Log (AUCt) –Log (AUCR) must fit between 80%-125%
  • 33. Bioanalytical Method Validation Method Validation should include Accuracy Precision Sensitivity Specificity Recovery Stability
  • 34. Bioanalytical Method Validation  Accuracy Closeness of determined value to the true Value The acceptance criteria is mean value < 15% deviation from the true value. At LOQ(limit of quantification), 20% deviation is acceptable
  • 35. Bioanalytical Method Validation  Precision The closeness of replicate determinations of a sample by an assay The acceptance criteria is < 15% CV,(closeness value) at 20% LOQ(limit of quantification)
  • 36. Bioanalytical Method Validation  Sensitivity The limit of quantitation is the lowest concentration which can be measured with acceptable accuracy and precision  Selectivity Ability of the method to measure only what it is intended to measure in the presence of other components in the sample. Blank samples of the biological matrix should be tested for the interfering peak.
  • 37. Bioanalytical Method Validation  Recovery The extraction efficiency of an analytical process, reported as an percentage of the known amount of an analyte. Recovery does not have to be 100% but the extent of recovery of internal standard and analyte should be consistent.
  • 38. Bioanalytical Method Validation  Stability During, sample collection , sample storage and sample analysis process, the stability of drug in matrix should be conducted
  • 39. Conclusion  Establish that a new formulation has therapeutic equivalence in the rate and extent of absorption to the reference drug product.  Important for linking the commercial drug product to clinical trial material at time of NDA.  Important for post-approval changes in the marketed drug formulation.
  • 40. References  D.M.Brahmankar, S.B.Jaiswal Biopharmaceutics and Pharmacokinetics A Treatise Vallabh Prakashan pg.no.315-363.